Comparing Intravenous Hydromorphone to Usual Care

Summary

In this randomized controlled trial, 2 mg intravenous (IV) hydromorphone will be more efficacious than usual care (usual care is analgesic management according to the judgment of the attending physician caring for that patient) in emergency department (ED) patients aged 21-64 years. The primary efficacy outcomes are the proportion of patients in each arm who choose to forgo additional pain medication in 30 minutes of entry into the study and the change in numerical rating scale (NRS) pain scores from baseline to 30 minutes post baseline.

Timeline

Start

2010-03

Primary completion

2010-11

Completion

2010-11

Outcome

Met primary endpoint

paper Additional pain medication was declined by 77.4% of patients in the 2 mg hydromorphone group at 30 minutes, compared to 65.8% in the usual care group. PMID 23406078 ↗

paper This difference of 11.6% was statistically and clinically significant (95% confidence interval [CI] = 1.8% to 21.1%). PMID 23406078 ↗

Publications

• Chang AK, Bijur PE, Lupow JB, John Gallagher E. Randomized clinical trial of efficacy and safety of a single 2-mg intravenous dose of hydromorphone versus usual care in the management of acute pain. Acad Emerg Med. 2013 Feb;20(2):185-92. doi: 10.1111/acem.12071.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Hydromorphone	Other / unclassified	2 mg	Intravenous

Indications

No indication recorded.